1	Lower Risks of Incident Colorectal Cancer in SGLT2i Users Compared to DPP4i Users: A
2	Propensity Score-matched Study with Competing Risk Analysis
3	Running Title: SGLT2i Reduces Risk of Incident Colorectal Cancer
4	Keywords: Diabetes mellitus; colorectal cancer; SGLT2 inhibitors; DPP4 Inhibitors
5	
6	Raymond Ngai Chiu Chan <sup>1</sup> , Robert Ngai Fung Chan <sup>1</sup> , Oscar Hou In Chou <sup>1</sup> , Teddy Tai Loy Lee <sup>1</sup> ,
7	Leonardo Roever MHS PhD <sup>2</sup> , Guoliang Li MD PhD <sup>3</sup> , Wing Tak Wong PhD <sup>4</sup> , Abraham Ka Chung
8	Wai MBChB FRCP <sup>5</sup> , Tong Liu MD PhD <sup>6</sup> , Gary Tse MD PhD FRCP FFPH FRCPath # <sup>1,6,7</sup> , Sharen
9	Lee MBChB # <sup>1</sup>
10	<sup>1</sup> Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration
11	<sup>2</sup> Department of Clinical Research, Federal University of Uberlandia, Uberlândia, Brazil
12	<sup>3</sup> Department of Cardiology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an,
13	China
14	<sup>4</sup> School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China
15	<sup>5</sup> Department of Emergency Medicine, School of Clinical Medicine, University of Hong Kong,
16	Hong Kong, China
17	<sup>6</sup> Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of
18	Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University,
19	Tianjin 300211, China
20	<sup>7</sup> Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, UK
21	
22	# Correspondence to:
23	Gary Tse, MD PhD FRCP FFPH FRCPath
24	Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

- 25 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of
- 26 Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin
- 27 300211, China
- 28 Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, UK
- 29 Email: gary.tse@kmms.ac.uk
- 30 Tel: +44 7309321109
- 31
- 32 Sharen Lee, MBChB
- 33 Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration
- 34 Email: <u>sharen212@gmail.com</u>
- 35

### 36 **Contribution of Authors**

- 37 RNCC and RNFC are responsible for study concept and design, analysis and interpretation of data,
- 38 drafting the manuscript, and statistical analysis. OHIC is responsible for study concept and design, as
- 39 well as acquisition of data. TTLL, LR, GL, WTW, AKCW, TL are responsible for study concept and
- 40 design, as well as critical revision of the manuscript for important intellectual content. GT and SL are
- 41 responsible for study concept and design, critical revision of the manuscript for important intellectual
- 42 content, and study supervision.
- 43

### 44 **Conflict of Interest**

45 None.

- 47 **Financial Support**
- 48 None.
- 49

# 50 Abstract

51	Background: Diabetes mellitus is associated with the development of colorectal cancer (CRC).
52	There have been a lack of study comparing the risk of colorectal cancer in sodium-glucose co-
53	transporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP4i), both of which
54	commonly prescribed second line agents for diabetes.
55	Methods: We conducted a territory wide retrospective cohort study on patients with type 2 diabetes
56	who was prescribed either of the two agents. Baseline demographics, use of other medications,
57	comorbidities and biochemical parameters were extracted. Propensity score matching was performed
58	to reduce the impacts of cofounders. Cause specific Cox regression was used to evaluate the risk of
59	incident colorectal cancer in SGLT2i users, as compared to DPP4i users. Subgroup analyses based
60	on age, gender and estimated glomerular filtration rate were performed.
61	Results: After propensity score matching, we included 13029 subjects who were prescribed SGLT2i
62	and DPP4i respectively. Incidence rate ratio of CRC was 0.566 (0.418-0.766) in SGLT2i users.
63	Overall, use of SGLT2i was associated with a lower risk of incident CRC (HR: 0.526; 95% CI:
64	0.382-0.724; P < 0.001). In subgroup analyses, use of SGLT2i was associated with lower risks of
65	incident CRC only in men (HR: 0.461; 95% CI: 0.303-0.702; P < 0.001), patients < 65 years old and
66	patients (HR:0.294; 95% CI: 0.174-0.496; P<0.001) with eGFR $\ge$ 45 mL/min/ 1.73m <sup>2</sup> (HR: 0.560;
67	95% CI: 0.395-0.792; P =0.001).
68	Conclusion: Use of SGLT2i may reduce risk of incident CRC as compared to use of DPP4i,
69	especially in younger male patients with fairly preserved renal function.

70

# 71 **INTRODUCTION**

72 Diabetes mellitus is a global public health issue affecting 536.6 million people worldwide in 73 2021<sup>1</sup>. Previous studies have established clear epidemiological links between diabetes mellitus and 74 various co-morbidities, including malignancies like liver, pancreatic, endometrial and colorectal cancers (CRC)<sup>2,3</sup>. A meta-analysis in 2013, which pooled data from 20 controlled trials and cohort 75 76 studies after 2007, reported a higher risk of incident CRC as well as a higher CRC-specific mortality 77 in diabetic patients<sup>4</sup>. Several groups have investigated the effects of anti-diabetic medications on the 78 risk of CRC. Metformin, an oral anti-hyperglycemic agent recommended by the American Diabetes 79 Association as the preferred initial pharmacologic treatment for type 2 diabetes mellitus (T2DM), was found to have a protective effect on incident CRC by several studies 5.7, although conflicting 80 results have been generated by other groups <sup>8-11</sup>. The effects of newer anti-diabetic medications, 81 82 especially dipeptidyl peptidase 4 inhibitors (DPP4i) and sodium-glucose co-transporter 2 inhibitors 83 (SGLT2i), were less studied. 84 DPP4i and SGLT2i are two emerging drug classes approved by the FDA for the treatment of T2DM<sup>12</sup>. Given the protective effects of DPP4i on pancreatic beta cells function, as well as the 85 86 cardioprotective and renoprotective effects of SGLT2i, both are increasingly prescribed as second line treatment for T2DM<sup>13-16</sup>. Preclinical studies on DPP4i and SGLT2i have highlighted their 87 potentials in CRC suppression <sup>17-19</sup>. Although there are few studies evaluating the effects of DPP4i 88

89 on CRC, most of them were of small scale and none directly compared it with SGLT2i<sup>20</sup>. Whether

90 any of these agents could alter the risk of incident CRC in T2DM patients remains unclear. Hence in

91 the present study, we aim to compare the risk of incident CRC in DPP4i and SGLT2i users amongst

92 T2DM patients using a large territory wide cohort in Hong Kong.

93

# 94 **METHODS**

#### 95 Study design and population

96 This was a territory-wide retrospective cohort study in T2DM patients treated with SGLT2i 97 or DPP4i between January 1st, 2016, and December 31st, 2019 in Hong Kong. Patients were 98 followed up until December 31st, 2020, or death, whichever came earlier. The current study was 99 approved by The Joint Chinese University of Hong Kong–New Territories East Cluster Clinical 100 Research Ethics Committee. Subjects were identified from the Clinical Data Analysis and Reporting 101 System (CDARS) of the Hospital Authority in Hong Kong. It is a territory-wide database that 102 centralizes patient information from all public hospitals and clinics in Hong Kong, which facilitates 103 retrieval of clinical characteristics, disease diagnosis, laboratory results and drug treatment details. It has been used by local teams in Hong Kong to conduct studies on T2DM<sup>21-23</sup>, and recently by our 104 team comparing the cardiovascular outcomes between SGLT2I and DPP4I users<sup>24-26</sup>. 105 106 Patients were excluded if any of the following criteria were met: 1) less than one year of drug 107 exposure; 2) on both DPP4I and SGLT2I, or switched between the two drug classes; 3) died within 108 30 days after initial drug exposure; 4) less than 18 years old at the start of the study; 5) pregnancy; 6) 109 without complete demographics 7) with no HbA1c records at baseline; 8) with a history of colorectal 110 cancer prior to baseline. 111 Patients' demographics, clinical and biochemical data were extracted for the present study. 112 Comorbidities at baseline were defined and extracted using the International Classification of 113 Diseases Ninth Edition (ICD-9) codes (Supplementary Table 1). Charlson's standard comorbidity 114 index was calculated. Use of anti-diabetic and lipid-lowering agents were extracted. Baseline 115 biochemistry, including the complete blood count, renal function tests, liver function tests, lipid and 116 glycemic profiles were extracted. Estimated glomerular filtration rate (eGFR) was calculated by the abbreviated modification of diet in renal disease (MDRD) formula <sup>27</sup>. 117 118 119 Adverse outcomes and statistical analysis

120 The primary endpoint of the present study was incident colorectal cancer (ICD-9: 153-154).

Mortality data were obtained from the Hong Kong Death Registry, a population-based official
government registry with the registered death records of all Hong Kong citizens linked to CDARS.
The endpoint date of interest for eligible patients was the event presentation date. The endpoint for
those without primary outcome presentation was the mortality date or the endpoint of the study
(December 31st, 2020).

126 For baseline clinical characteristics, continuous and categorical variables were presented as 127 mean (standard deviation [SD]) and frequency (percentage) respectively. Propensity score matching 128 (PSM) with a 1:1 ratio for SGLT2i users versus DPP4i users based on age, gender, Charlson's 129 comorbidity index, other comorbidities and non-SGLT2I/ DPP4I medications was performed using 130 the nearest neighbor search strategy. Baseline characteristics between patients with SGLT2i and 131 DPP4i use before and after matching were compared with standardized mean difference (SMD), with 132 SMD<0.20 regarded as well-balanced. The incidence of new-onset colorectal cancer was derived 133 from dividing the number of outcomes by person-year at risks, which estimate the number of years at 134 risks. Cause specific hazard models were used to calculate the unadjusted and adjusted hazard ratios. 135 Important covariates were adjusted by backward selection. HDL was considered as a surrogate 136 marker of BMI and was adjusted in addition to other covariates. It has been shown to correlate better with BMI as compared to other serum lipids <sup>28-31</sup>. Fine Gray's subdistribution hazard models were 137 138 conducted as sensitivity analyses. Subgroup analyses were performed in patients  $\geq 65$  years old, < 65139 years old, male and female. We aimed to evaluate the impact of renal function on the effects of 140 SGLT2i and/or DPP4i, hence subgroup analyses were also performed in patients with eGFR > 45141 mL/min/ 1.73m<sup>2</sup> and <45 mL/min/ 1.73m<sup>2</sup> respectively. The hazard ratios (HR), 95% CI and P-value 142 were reported. Statistical significance was taken as P-value < 0.05. All statistical analyses were 143 performed with RStudio software (Version: 1.1.456).

144

145 **RESULTS** 

### 146 Baseline characteristics of the study population

147	In this retrospective cohort study, 86 353 patients in Hong Kong using SGLT2i/DPP4i
148	between January 1 <sup>st</sup> , 2016 and December 31 <sup>st</sup> , 2019 were recruited. They were followed up until
149	December 31 <sup>st</sup> , 2020 or deaths, which ever came earlier. Patients with less than one month of drug
150	exposure (n = 3019), on both DPP4i and SGLT2i (n = 13529), died within 30 days after initial drug
151	exposure (n = 4491), less than 18 years old at baseline (n = 592), less than 1 year of drug exposure (n
152	= 1781), pregnancy (n = 19), without complete demographics or mortality data (n = 15), without
153	baseline HbA1c (n = 9766), with CRC prior to baseline (n = 289) were excluded.
154	Subsequently, 18 741 SGLT2i users and 33 839 DPP4i users were included. After 1:1
155	propensity score matching, 13 029 patients on SGLT2i and DPP4i respectively entered statistical
156	analyses. In the matched cohort, 65 (0.5%) SGLT2i users and 118 (0.9%) DPP4i users developed
157	incident CRC. The baseline characteristic of patients before and after PSM are shown in
158	Supplementary Table 2 and Table 1 respectively.
159	
160	SGLT2i use is associated with reduced risk of incident CRC
161	Over a follow-up period of 117734.1 person-years, 183 incident CRC were identified.
162	Overall, the incidence of CRC (IRR: 0.566; 95% CI: 0.418-0.766; P<0.001) were lower amongst
163	SGLT2i users compared to DPP4i users after PSM (Table 2). We used univariable Cox regression to
164	identify the potential risk factors of incident CRC before and after PSM, which were serially adjusted
165	in subsequent multivariable models (Supplementary Table 3 and 4). Unadjusted and adjusted
166	hazard ratios for incident CRC were presented in Table 3. In all models, use of SGLT2i was

- 167 significantly associated with lower risks of incident CRC as compared to use of DPP4i. After
- adjusting for age, gender, HbA1c, use of other medications, comorbidities and HDL, use of SGLT2i
- 169 was associated with an approximately 47.4% reduction in the risk of incident CRC (HR: 0.526; 95%
- 170 CI: 0.382-0.724; P<0.001).

171	Sensitivity analyses were performed using Fine-Gray's subdistribution regression model to
172	confirm the predictiveness of the models. Similarly, use of SGLT2i was associated with lower risks
173	of incident CRC in the sensitivity analyses after serial adjustment of important covariates identified
174	in univariable analyses (Supplementary Table 5). In model 5, use of SGLT2i was associated with a
175	42.5% reduction in risk of incident CRC (HR: 0.575; 95% CI: 0.368-0.896; P= 0.015).
176	
177	Effects of SGLT2i on the risk of incident CRC stratified by age and gender
178	Sub-group analyses based on age and gender were further performed. In male, use of SGLT2i
179	was associated with lower risks of incident CRC (HR: 0.461; 95% CI: 0.303-0.702; P < 0.001) but no
180	significant association was found in female (Table 4). Similar results were reproduced in the
181	sensitivity analyses using Fine-Gray's subdistribution hazard models (HR: 0.505; 95% CI: 0.339-
182	0.752; P <0.001) (Supplementary Table 6). In patients younger than 65 years old, use of SGLT2i
183	was associated with reduced risks of incident CRC (HR: 0.294; 95% CI: 0.174-0.496; P < 0.001)
184	whereas no significant association was found in the older group (Table 5). Again, similar results
185	were observed in sensitivity analyses (HR: 0.328; 95% CI: 0.198-0.546; P<0.001). (Supplementary
186	Table 7)
187	
188	Effects of SGLT2i on the risk of incident CRC stratified by eGFR
189	To assess the impact of eGFR on the effects of SGLT2i, we conducted subgroup analyses
190	based on the eGFR. As the number of incident CRC in patients with eGFR< 45 mL/min/ $1.73m^2$ is
191	inadequate to perform a robust analysis, the unmatched cohort were used. In patients with $eGFR \ge 45$
192	mL/min/ 1.73m <sup>2</sup> , use of SGLT2i was correlated with a significantly reduced risk of incident CRC
193	(HR: 0.560; 95% CI: 0.395-0.792; $P = 0.001$ ). However, in patients with more advanced CKD, the
194	association was lost. (Table 6) Sensitivity analyses yielded similar findings (Supplementary Table
195	8).

200 were, again, performed in the unmatched cohort. Use of SGLT2i was not associated with lower risks	200 201	were, again, performed in the unmatched cohort. Use of SGLT2i was not associated with lower risks of all-cause mortality (HR: $0.285$ ; 95% CI: $0.066-1.25$ ; P = $0.097$ ) after adjusted for age, gender
	199	users. Given the limited number of deaths with incident CRC in the matched cohort, the analyses
199 users. Given the limited number of deaths with incident CRC in the matched cohort, the analyses	198	We compared the all-cause mortality of patients with incident CRC amongst SGLT2i and DPP4i
	197	SGLT2i use is associated with lower all-cause mortality in patients who developed incident CRC

203

#### 204 **DISCUSSION**

205 In the present study, we used a territory-wide cohort to compare the risk of incident CRC 206 amongst SGLT2i and DPP4i users. To our knowledge, this is the first study thus far to evaluate the 207 incidence of CRC amongst patients treated with the named medications. Importantly, we were able 208 to demonstrate several clinically relevant findings: 1) use of SGLT2i was associated with a lower 209 risk of incident CRC after serial adjustment. 2) The effects of SGLT2i on incident CRC, as compared 210 to DPP4i, differ with respect to patients' age, gender and renal function. 3) Use of SGLT2i may not reduce all-cause mortality in DM patients with incident CRC. These findings are of clinical 211 212 significance as SGLT2i and DPP4i are both commonly prescribed second line pharmacological 213 treatment for T2DM.

214

### 215 SGLT2i Reduce Risk of Incident CRC via an eGFR-Dependent Pathway

Diabetes mellitus and insulin resistance have been recognized to be major risk factors of various malignancies including CRC, although the exact mechanism remains unclear <sup>2, 3</sup>. Hyperinsulinemia, which characterizes pre-diabetes and early diabetes, was known to promote cancer cell survival and mitogenesis via binding to insulin and insulin-like growth factor (IGF) receptors that are widely expressed on cancer cells membrane <sup>32-34</sup>. Other mechanisms, such as

upregulation of inflammatory cytokines, alterations of cellular energetics and shared risk factors,
have previously been proposed <sup>2, 35</sup>. In view of the epidemiological and biological links between
CRC and diabetes mellitus, studies have investigated the relationship between different anti-diabetic
medications and incident CRC.

225 Currently, there is a lack of evidence on the effects of SGLT2i, a relatively new agent for T2DM that inhibits SGLT2 in the kidney to promote glycosuria, on incident CRC<sup>36</sup>. In contrary to 226 227 most anti-diabetic medications, its major mechanism of action is independent of insulin. Studies 228 suggested that use of SGLT2i improved insulin sensitivity and potentially lowers plasma insulin 229 level <sup>37, 38</sup>. Preclinical animal models echoed this finding by showing a dramatically reduced plasma insulin in SGLT2 knockout mice<sup>39</sup>. Furthermore, use of SGLT2i has been shown to improve shared 230 231 risk factors between CRC and diabetes, reduce circulating inflammatory cytokines, attenuate 232 vascular endothelial and smooth muscle cells proliferation in response to interleukins, alter cellular 233 energetics and suppress oxidative stress, all of which may be protective factors against malignancies such as CRC <sup>37, 40-42</sup>. However, whether SGLT2i reduces risk of incident CRC and the actual 234 235 mechanisms, if any, remain unknown.

236 In the present study, we demonstrated that SGLT2i significantly reduced the risk of incident 237 CRC, and the association was only significant when the eGFR was  $\geq 45$  mL/min/ 1.73m<sup>2</sup>. 238 Apparently, the glycosuria effects of SGLT2i depends on relatively preserved glomerular function. A 239 previous study suggested that the glucose lowering effect of SGLT2i was attenuated when the eGFR 240 dropped to < 45 mL/min/  $1.73m^2$ , while another suggested that the effect was lost when the eGFR dropped to  $<30 \text{ mL/min}/1.73 \text{m}^{2}$ <sup>43, 44</sup>. In our study, we were able to demonstrate that the protective 241 242 effect of SGLT2i against incident CRC, as compared to DPP4i, was independent of glycemic control 243 by adjusting for HbA1c, but the association was lost when the eGFR was below 45 mL/min/ 1.73m<sup>2</sup>. 244 Hence, it is reasonable to hypothesize that SGLT2i may reduce the risk of incident CRC via its 245 glycosuria effect, which reduces circulating insulin level at any given blood glucose level and

downregulates farnesylatesd Ras protein to supress mitogenesis <sup>45</sup>. Although the role of chronic inflammation and SGLT2 expression on CRC cell lines has been previously implicated, a recent study showed that oral administration of SGLT2i in obese and diabetic mice with azoxymethaneinduced colorectal pre-neoplastic lesions appeared to reduce IGF-1 and several related signaling molecules in the colonic mucosa, while direct administration of SGLT2i on human CRC cell lines exhibited no impacts on cellular proliferation, further supporting our hypothesis <sup>46</sup>. Further investigations are warranted to validate these findings.

253

# 254 Differential effects of SGLT2i across gender and age

In the present study, we also demonstrated that SGLT2i only reduced risk of incident CRC in male and younger patients, but not their female or older counterparts. In fact, gender dimorphism in CRC in terms of the incidence, molecular pathogenesis and prognosis have been previously reported <sup>47, 48</sup>. Lifestyle factors, hormonal differences, and more recently single nucleotide polymorphisms or genetic variants have been proposed to explain these differences <sup>49-52</sup>.

260

261 Several epidemiological studies have suggested that the relationship between obesity and CRC is 262 stronger in male than female, potentially due to the fact the protective effect of estrogen over insulin resistance and subsequent hyperinsulinemia <sup>53-57</sup>. Recent studies also suggested the insulin-IGF axis 263 is preferentially upregulated in men with CRC <sup>58, 59</sup>. Differences in the level and biological action of 264 265 insulin and IGF across the two genders may potentially account for the discrepancy. Meanwhile, 266 elderly patients with T2DM may have relatively less preserved pancreatic  $\beta$ -cell function and renal 267 function while insulin sensitivity appeared to be similar in older and younger subjects with comparable BMI <sup>60-62</sup>. These may limit the effects of SGLT2i on preventing incident CRC. 268

269

270 Strengths and limitations

271 With the use of medical records from a territory-wide database, CDARS, our study was able 272 to detect relatively rare outcomes, such as incident CRC, with an adequate sample size and follow-up 273 duration. The present study was also the first to compare the difference in CRC incidence amongst 274 T2DM patients treated with SGLT2i and DPP4i. Subgroup analyses in our study may also provide 275 mechanistic insight into the anti-tumour effects of SGLT2i. However, there are still certain limitation 276 in our study. First, although CDARS has been considered a relatively reliable source of clinical data, 277 there was unavoidably information bias due to the risk of under-coding, coding errors and missing 278 data. Second, BMI has been considered an important risk factor of CRC but was not available in our 279 database. The use of HDL as a surrogate marker may potentially and partially adjust for this 280 limitation. Third, the retrospective nature of our study did not allow measurement of drug 281 concentration, which might correlate with the outcomes. Fourth, the present study aimed at assessing 282 the epidemiological links between use of SGLT2i and DPP4i with incident CRC and could not 283 address the causal or mechanistic relationship. Lastly, SGLT2I and DPP4I are drug classes 284 constituting a variety of agents from different brands with their respective formula. The present study 285 did not conduct further analyses to compare the effects of different agents in the same drug class. 286 287 CONCLUSION 288 SGLT2i use is associated with a reduced risk of incident CRC compared to DPP4i use. The 289 association was significant only in younger patients, male and in patients with an eGFR  $\geq 45$ mL/min/ 1.73m<sup>2</sup>. SGLT2i use was not associated with a lower all-cause mortality in diabetic patients 290 291 with incident CRC. Further studies are warranted to validate the findings.

292

# ACKNOWLEDGEMENTS

Nil

# **CONFLICT OF INTEREST**

Nil

# FUNDING

Nil

### REFERENCES

- 1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119.
- 2. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and Cancer: A consensus report. Diabetes Care 2010;33:1674-1685.
- 3. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-23.
- 4. De Bruijn KM, Arends LR, Hansen BE, et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 2013;100:1421-9.
- 5. Sehdev A, Shih YC, Vekhter B, et al. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer 2015;121:1071-8.
- 6. Chang YT, Tsai HL, Kung YT, et al. Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes-A Nationwide Cohort Study. Transl Oncol 2018;11:535-541.
- 7. Rennert G, Rennert HS, Gronich N, et al. Use of metformin and risk of breast and colorectal cancer. Diabetes Res Clin Pract 2020;165:108232.
- 8. Spillane S, Bennett K, Sharp L, et al. Metformin exposure and disseminated disease in patients with colorectal cancer. Cancer Epidemiology 2014;38:79-84.
- 9. Shin CM, Kim N, Han K, et al. Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study. Cancer Epidemiology 2020;64:101658.
- 10. Cardel M, Jensen SM, Pottegard A, et al. Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. Cancer Med 2014;3:1458-66.
- 11. Lin CM, Huang HL, Chu FY, et al. Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. PLoS One 2015;10:e0125421.
- 12. Ferro EG, Michos ED, Bhatt DL, et al. New Decade, New FDA Guidance for Diabetes Drug Development. Journal of the American College of Cardiology 2020;76:2522-2526.
- 13. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:642-653.

- 14. Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation 2017;136:1643-1658.
- 15. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 2016;134:752-72.
- 16. Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. Am J Kidney Dis 2018;72:267-277.
- 17. Nasiri AR, Rodrigues MR, Li Z, et al. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer & Metabolism 2019;7:10.
- 18. Kato J, Shirakami Y, Ohnishi M, et al. Suppressive effects of the sodium □ glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. Oncol Rep 2019;42:2797-2805.
- 19. Amritha CA, Kumaravelu P, Chellathai DD. Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study. J Clin Diagn Res 2015;9:Fc14-6.
- 20. Overbeek JA, Bakker M, van der Heijden A, et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev 2018;34:e3004.
- 21. Lee S, Liu T, Zhou J, et al. Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study. Acta Diabetol 2021;58:171-180.
- 22. Lee S, Zhou J, Guo CL, et al. Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death. Endocrinol Diabetes Metab 2021;4:e00240.
- 23. Lee S, Jeevaratnam K, Liu T, et al. Risk stratification of cardiac arrhythmias and sudden cardiac death in type 2 diabetes mellitus patients receiving insulin therapy: A population-based cohort study. Clin Cardiol 2021;44:1602-1612.
- 24. Lee S, Zhou J, Leung KSK, et al. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong. Cardiovasc Drugs Ther 2022.
- 25. Zhou J, Lee S, Leung KSK, et al. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. ESC Heart Fail 2022;9:1388-1399.
- Mui JV, Zhou J, Lee S, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis. Front Cardiovasc Med 2021;8:747620.
- 27. Soliman AR, Fathy A, Khashab S, et al. Comparison of abbreviated modification of diet in renal disease formula (aMDRD) and the Cockroft-Gault adjusted for body surface (aCG) equations in stable renal transplant patients and living kidney donors. Ren Fail 2013;35:94-7.
- 28. Erem C, Hacihasanoglu A, Deger O, et al. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine 2008;34:36-51.
- 29. Stepien A, Stepien M, Wlazel RN, et al. Assessment of the relationship between lipid parameters and obesity indices in non-diabetic obese patients: a preliminary report. Med Sci Monit 2014;20:2683-8.
- 30. Boyd GS, Koenigsberg J, Falkner B, et al. Effect of obesity and high blood pressure on plasma lipid levels in children and adolescents. Pediatrics 2005;116:442-6.

- 31. Kucukhuseyin O, Kurnaz O, Akadam-Teker AB, et al. The association of MTHFR C677T gene variants and lipid profiles or body mass index in patients with diabetic and nondiabetic coronary heart disease. J Clin Lab Anal 2013;27:427-34.
- 32. Zhang H, Pelzer AM, Kiang DT, et al. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7.
- 33. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009;7:14.
- 34. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109S-20S.
- 35. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
- 36. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2017;24:73-79.
- 37. Xu L, Nagata N, Nagashimada M, et al. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine 2017;20:137-149.
- 38. Yaribeygi H, Sathyapalan T, Maleki M, et al. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sci 2020;240:117090.
- 39. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011;60:890-8.
- 40. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 2018;44:457-464.
- 41. Sukhanov S, Higashi Y, Yoshida T, et al. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1beta and IL-18 secretion. Cell Signal 2021;77:109825.
- 42. Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1betastimulated cytokine and chemokine secretion in vascular endothelial cells by AMPactivated protein kinase-dependent and -independent mechanisms. Sci Rep 2018;8:5276.
- 43. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-71.
- 44. Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018;93:231-244.
- 45. Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. Diabetol Metab Syndr 2011;3:10.
- 46. Kato J, Shirakami Y, Ohnishi M, et al. Suppressive effects of the sodiumglucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. Oncol Rep 2019;42:2797-2805.
- 47. Yang Y, Wang G, He J, et al. Gender differences in colorectal cancer survival: A meta-analysis. Int J Cancer 2017;141:1942-1949.

- 48. White A, Ironmonger L, Steele RJC, et al. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer 2018;18:906.
- 49. Tan SC, Suzairi MS, Aizat AA, et al. Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer. Med Oncol 2013;30:693.
- 50. Martinelli M, Scapoli L, Cura F, et al. Colorectal cancer susceptibility: apparent gender-related modulation by ABCB1 gene polymorphisms. J Biomed Sci 2014;21:89.
- 51. Conti L, Del Corno M, Gessani S. Revisiting the impact of lifestyle on colorectal cancer risk in a gender perspective. Crit Rev Oncol Hematol 2020;145:102834.
- 52. Nussler NC, Reinbacher K, Shanny N, et al. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend Med 2008;5:209-17.
- 53. West DW, Slattery ML, Robison LM, et al. Dietary intake and colon cancer: sex- and anatomic site-specific associations. Am J Epidemiol 1989;130:883-94.
- 54. Mao Y, Pan S, Wen SW, et al. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. Int J Cancer 2003;105:831-7.
- 55. Slattery ML, Caan BJ, Potter JD, et al. Dietary energy sources and colon cancer risk. Am J Epidemiol 1997;145:199-210.
- 56. Morimoto LM, Newcomb PA, White E, et al. Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:1204-11.
- 57. De Paoli M, Zakharia A, Werstuck GH. The Role of Estrogen in Insulin Resistance: A Review of Clinical and Preclinical Data. Am J Pathol 2021;191:1490-1498.
- 58. Zeljkovic A, Mihajlovic M, Stefanovic A, et al. Potential use of serum insulin-like growth factor 1 and E-cadherin as biomarkers of colorectal cancer. Colorectal Dis 2020;22:2078-2086.
- 59. Yamaji T, Iwasaki M, Sasazuki S, et al. Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia. Int J Obes (Lond) 2012;36:440-7.
- 60. Bellary S, Kyrou I, Brown JE, et al. Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat Rev Endocrinol 2021;17:534-548.
- 61. Amati F, Dube JJ, Coen PM, et al. Physical inactivity and obesity underlie the insulin resistance of aging. Diabetes Care 2009;32:1547-9.
- 62. Karakelides H, Irving BA, Short KR, et al. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes 2010;59:89-97.



Figure 1: Flow Diaphragm for Subjects Selection and Propensity Score Matching

Characteristics	SGLT2I Users	DPP4I Users	SMD
Demographic Male	7350 (56.4)	7122 (54.7)	0.035
			0.033
Age Follow-up Duration	60.4 (10.8)	61.2 (11.2)	0.075
Charlson's Score	1810 (104)	1770 (205)	0.042
Charlson's Score	1.81 (1.26)	1.87 (1.33)	0.043
Microvascular Complications			
Diabetic Retinopathy	795 (6.10)	693 (5.32)	0.034
Diabetic Nephropathy	8454 (64.9)	8497 (65.2)	0.007
Diabetic Neuropathy	212 (1.63)	181 (1.39)	0.020
Macrovascular Complications			
Heart Failure	396 (3.04)	294 (2.26)	0.049
Acute Myocardial Infarct	398 (3.05)	331 (2.54)	0.031
Stroke/ Transient Ischemic Attack	402 (3.09)	394 (3.02)	0.004
Atrial Fibrillation	394 (3.02)	243 (1.87)	0.075
Other Comercidities			
<b>Other Comorbidities</b> Hyperlipidemia	416 (3.19)	332 (2.55)	0.039
Hypertension	3242 (24.9)	2947 (22.6)	0.053
Immune Mediated Enterocolitis	714 (5.48)	617 (4.74)	0.034
Other Cancer	286 (2.20)	308 (2.36)	0.011
Anti-Diabetic and Lipid-Lowering Medications			
Metformin	12133 (93.1)	12202 (93.7)	0.021
Sulphonylurea	10282 (78.9)	10649 (81.7)	0.021
Insulin	6240 (47.9)	5645 (43.3)	0.071
Acarbose	374 (2.87)	342 (2.62)	0.012
Thiazolidinedione	2843 (21.8)	2470 (19.0)	0.013
Glucagon-Like-Peptide Agonist	240 (1.84)	146 (1.12)	0.060
Statins	9915 (76.1)	9636 (74.0)	0.000
Complete Blood Count Red Cell Count	4.70 (0.58)	4.52 (0.689)	0.276
Mean Corpuscular Volume	87.0 (7.25)	87.0 (7.77)	0.276
Mean Corpuscular Hemoglobin Concentration	29.3 (2.89)	29.4 (3.13)	0.003
White Cell Count	7.89 (2.55)	8.07 (2.92)	0.049
Neutrophil	5.06 (2.35)	5.42 (2.92)	0.000
Lymphocyte			0.133
Neutrophil to Lymphocyte Ratio	2.13 (0.956) 2.97 (3.63)	1.97 (0.802) 3.68 (4.82)	0.179
Eosinophil	0.212 (0.185)	0.211 (0.217)	0.104
Platelet	242 (67.7)	243 (72.6)	0.008
Platelet to Lymphocyte Ratio	134 (176)	148 (144)	0.012
Renal Function Test Sodium	139.2 (2.75)	139.2 (2.90)	< 0.00
Potassium	4.31 (0.44)	4.34 (0.481)	0.055
Urea	5.72 (1.96)	6.34 (3.53)	0.000
Creatinine	78.7 (28.3)	92.9 (87.9)	0.210
Estimated Glomerular Filtration Rate	83.4 (22.2)	78.6 (26.5)	0.196
Liver Function Test			
Liver Function Test Alkaline Phosphatase	74.2 (26.8)	78.1 (33.4)	0.126
Aspartate Transaminase	28.0 (29.0)	27.8 (34.8)	0.120
Alanine Transaminase	31.5 (29.9)	29.3 (31.8)	0.007
Bilirubin	11.6 (6.27)		0.073
Protein	74.4 (4.95)	11.4 (6.21) 73.5 (5.54)	0.028
Albumin	42.5 (3.28)	41.6 (4.08)	0.103
	12.5 (5.20)	11.0 (4.00)	0.230
Lipid Profile	1.70 (1.64)	1 (0 (1 40)	0.00
Triglyceride	1.72 (1.64)	1.68 (1.40)	0.026
Total Cholesterol	4.31 (0.990)	4.39 (0.971)	0.080
High-Density Lipoprotein	1.18 (0.315)	1.20 (0.326)	0.079
Low-Density Lipoprotein	2.38 (0.790)	2.44 (0.800)	0.084
Glucose Control			
Glycated Hemoglobin	8.06 (1.72)	8.06 (1.71)	0.003

Outcomes		
Death	346 (2.66)	1062 (8.15)
Incident CRC	65 (0.499)	118 (0.906)

Table 1: Baseline Demographics of SGLT2i and DPP4i Users after Propensity Score Matching

		Number of Event	IR [95% CI]	IRR [95% CI]
	Be	fore Propensity Scor	e Matching	
Overall	252767	471	1.86 [1.70-2.04]	-
DPP4i Users	159796.7	377	2.36 [2.13-2.61]	-
SGLT2i Users	92970.32	94	1.01 [0.817-1.24]	0.429 [0.342-0.537]

After Propensity Score Matching					
Overall	117734.1	183	1.55 [1.34-1.80]	-	
DPP4i Users	58083.66	118	2.03 [1.68-2.43]	-	
SGLT2i Users	59650.41	65	1.09 [0.841-1.39]	0.566 [0.418-0.766]	
TT 1 1 0 4	1. 1.7 .1 .	CODO 10		1 C D . C	

Table 2: Annualized Incidence Rate of CRC per 1000 Person-Year before and after Propensity Score Matching.

	Hazard ratios	95% CI	P-value			
Before Propensity Score Matching						
Model 1	0.424	0.338-0.531	< 0.001			
Model 2	0.599	0.474-0.760	< 0.001			
Model 3	0.599	0474-0.759	< 0.001			
Model 4	0.579	0.444-0.758	< 0.001			
Model 5	0.588	0.449-0.769	< 0.001			
Model 6	0.572	0.431-0.759	0.001			
After Propensity Score Matching						
Model 1	0.531	0.392-0.719	< 0.001			
Model 2	0.548	0.405-0.742	< 0.001			
Model 3	0.548	0.405-0.742	< 0.001			
Model 4	0.537	0.397-0.728	< 0.001			
Model 5	0.535	0.395-0.725	< 0.001			
Model 6	0.526	0.382-0.724	< 0.001			

#### Table 3: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of medications, comorbidities, and HDL.

	Hazard ratios	95% CI	<b>P-value</b>			
Male						
Model 1	0.467	0.314-0.692	< 0.001			
Model 2	0.481	0.324-0.714	< 0.001			
Model 3	0.480	0.323-0.713	< 0.001			
Model 4	0.481	0.324-0.715	< 0.001			
Model 5	0.478	0.322-0.710	< 0.001			
Model 6	0.461	0.303-0.702	< 0.001			
Female						
Model 1	0.639	0.398-1.03	0.064			
Model 2	0.481	0.324-0.714	0.097			
Model 3	0.670	0.417-1.08	0.098			
Model 4	0.624	0.388-1.01	0.053			
Model 5	0.624	0.387-1.01	0.053			
Model 6	0.616	0.374-1.01	0.056			

Table 4: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching in Patient Subgroup Stratified by Gender

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age. Model 3: Adjusted for age and HbA1c. Model 4: Adjusted for age, HbA1c and use of other medications. Model 5: Adjusted for age, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, HbA1c, use of other medications, comorbidities and HDL.

	Hazard ratios	95% CI	P-value		
Subjects < 65 Years Old					
Model 1	0.347	0.210-0.692	< 0.001		
Model 2	0.341	0.206-0.562	< 0.001		
Model 3	0.341	0.207-0.562	< 0.001		
Model 4	0.321	0.194-0.530	< 0.001		
Model 5	0.321	0.195-0.531	< 0.001		
Model 6	0.294	0.174-0.496	< 0.001		
Subject ≥ 65 Years Old					
Model 1	0.727	0.493-1.07	0.107		
Model 2	0.738	0.501-1.09	0.126		
Model 3	0.737	0.500-1.09	0.124		
Model 4	0.735	0.498-1.09	0.122		
Model 5	0.722	0.489-1.07	0.102		
Model 6	0.767	0.505-1.16	0.211		

Table 5: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching in Patient Subgroup Stratified by Age

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of other medications, comorbidities and HDL.

	Hazard ratios	95% CI	<b>P-value</b>	
eGFR ≥ 45mL/min/ 1.73m <sup>2</sup>				
Model 1	0.474	0.359-0.624	< 0.001	
Model 2	0.605	0.454-0.807	< 0.001	
Model 3	0.605	0.454-0.807	< 0.001	
Model 4	0.570	0.409-0.795	< 0.001	
Model 5	0.580	0.416-0.809	0.001	
Model 6	0.560	0.395-0.792	0.001	
eGFR < 45mL/min/ 1.73m <sup>2</sup>				
Model 1	0.480	0.177-1.31	0.151	
Model 2	0.549	0.201-1.50	0.243	
Model 3	0.551	0.202-1.51	0.245	
Model 4	0.472	0.158-1.41	0.178	
Model 5	0.480	0.161-1.44	0.189	
Model 6	0.524	0.173-1.59	0.253	

Table 6: Univariable and Multivariable Cause-Specific Cox Regression before Propensity Score Matching in Patient Subgroup Stratified by eGFR

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of medications, comorbidities and HDL.